© The American Society of Gene & Cell Therapy original article Minicircle DNA-based Gene Therapy Coupled With Immune Modulation Permits Long-term Expression of α-l-Iduronidase in Mice With
暂无分享,去创建一个
G. Freeman | M. Kay | J. Tolar | L. Naldini | Zhi-Ying Chen | B. Blazar | Mark J. Osborn | A. DeFeo | R. McElmurry | C. Lees | G. Freeman
[1] A. Schambach,et al. A Self-inactivating γ-Retroviral Vector Reduces Manifestations of Mucopolysaccharidosis I in Mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] J. Tolar,et al. Gender-related dimorphism in aortic insufficiency in murine mucopolysaccharidosis type I. , 2009, The Journal of heart valve disease.
[3] J. Parker,et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] J. Wolff,et al. Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery. , 2009, Human gene therapy.
[5] Dexi Liu,et al. Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] J. Tolar,et al. α-L-iduronidase therapy for mucopolysaccharidosis type I , 2008, Biologics : targets & therapy.
[7] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[8] G. Freeman,et al. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. , 2008, Blood.
[9] K. Ponder,et al. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice , 2008, The journal of gene medicine.
[10] M. Mcentee,et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. , 2008, The Journal of clinical investigation.
[11] S. E. Barker,et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis , 2008, Gene Therapy.
[12] M. Kay,et al. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] D. Jaeck,et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human , 2008, Cancer Gene Therapy.
[14] A. Annoni,et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. , 2007, Blood.
[15] Luigi Naldini,et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state , 2007, Nature Biotechnology.
[16] William Stafford Noble,et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.
[17] L. Belur,et al. Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidoses , 2007, The journal of gene medicine.
[18] K. Ponder,et al. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] K. Ponder,et al. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. , 2007, Molecular genetics and metabolism.
[20] L. Naldini,et al. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. , 2006, Human gene therapy.
[21] Bin Wang,et al. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] L. Naldini,et al. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.
[23] S. Ekker,et al. Dynamic gene expression after systemic delivery of plasmid DNA as determined by in vivo bioluminescence imaging. , 2005, Human gene therapy.
[24] J. Calvete,et al. Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles , 2005, Gene Therapy.
[25] M. Kay,et al. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. , 2005, Human gene therapy.
[26] A. Rudensky,et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). , 2005, Blood.
[27] M. Kay,et al. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. , 2005, Human gene therapy.
[28] L. Naldini,et al. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. , 2005, Human gene therapy.
[29] Seng H. Cheng,et al. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy , 2004, Expert opinion on drug delivery.
[30] I. Tsvetkova,et al. The Phenotypic Characters of the Stem Cells in Hepatocytes during Liver Regeneration: The Expression of the Bcrp1/Abcg2 Membrane Transporter and the Hoechst 33342 Export , 2004, Doklady Biological Sciences.
[31] M. Kay,et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo , 2004, Gene Therapy.
[32] M. Kay,et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] Shawn M. Burgess,et al. Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.
[34] Mark A. Kay,et al. Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.
[35] B. Brown,et al. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. , 2002, Blood.
[36] C. Walsh,et al. Induction of tolerance to human factor VIII in mice. , 2001, Blood.
[37] M. Kay,et al. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[39] G. Freeman,et al. ICOS is critical for CD40-mediated antibody class switching , 2001, Nature.
[40] J. Wolff,et al. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. , 1999, Human gene therapy.
[41] F. Jirik,et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. , 1997, Human molecular genetics.
[42] D. Sleat,et al. Ligand Binding Specificities of the Two Mannose 6-Phosphate Receptors* , 1997, The Journal of Biological Chemistry.
[43] J. Wraith,et al. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome) , 1995, Acta paediatrica.
[44] Luigi Naldini,et al. Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.
[45] J. Tolar,et al. Targeting of the CNS in MPS-IH Using a Nonviral Transferrin-α-l-iduronidase Fusion Gene Product. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] D. W. Emery,et al. The cHS4 chromatin insulator reduces gammaretroviral vector silencing by epigenetic modifications of integrated provirus , 2008, Gene Therapy.